| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 5,560,511 | 7,286,670 | 7,329,298 | NaN |
| Prepaid expenses | 229,025 | 54,691 | 72,819 | 75,288 |
| Cash | NaN | NaN | NaN | 754,323 |
| Total current assets | 5,789,536 | 7,341,361 | 7,402,117 | 829,611 |
| Total assets | 5,789,536 | 7,341,361 | 7,402,117 | 829,611 |
| Trade accounts payable and accrued liabilities | 279,615 | 536,769 | 329,375 | 254,956 |
| Due to officer | NaN | 155,518 | NaN | NaN |
| Accrued compensation - officer | NaN | 417,470 | NaN | NaN |
| Insurance loan payable | 202,869 | NaN | NaN | NaN |
| Due to related parties | 344,826 | 318,234 | 93,432 | 93,432 |
| Preferred stock, no par value, 100,000,000 shares authorized and none issued or outstanding | NaN | NaN | NaN | 0 |
| Total current liabilities | 827,310 | 1,427,991 | 422,807 | 348,388 |
| Common stock, no par value 300,000,000 shares authorized, 30,514,304 and 29,762,671 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | NaN | NaN | NaN | 0 |
| Total liabilities | 827,310 | 1,427,991 | 422,807 | 348,388 |
| Additional paid-in capital | 46,963,236 | 46,923,433 | 45,928,180 | 38,327,799 |
| Accumulated deficit | -42,001,010 | -41,010,063 | -38,948,870 | -37,846,576 |
| Total stockholders equity | 4,962,226 | 5,913,370 | 6,979,310 | 481,223 |
| Total liabilities and stockholders equity | 5,789,536 | 7,341,361 | 7,402,117 | 829,611 |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)